Darmstadt, Germany, January 25, 2017/Korea IT Times – Merck has introduced CAN MultiFlow™ screening services to more accurately predict genotoxic and mode of action*
properties of substances, ingredients and drug compounds. Offered through its BioReliance® testing facilities, Merck will be the first company to provide this service in the United States.
The screening process uses flow cytometry to quickly and efficiently screen for
clastogens, aneugens and non-genotoxicants (CAN) in pharmaceutical compounds,
agricultural chemicals, flavors, fragrances and consumer products. The results from
the assay can help manufacturers reject harmful substances during product
development or reduce undesirable properties at an early stage.
“Assessing toxicology is one of the most important steps in the development of
chemicals, ingredients and drugs for use in pharmaceuticals, agriculture or
consumer goods,” said Andrew Bulpin, Head of Process Solutions Strategic
Marketing & Innovation, Life Science. “Merck’s new CAN MultiFlow™ screening
services provide more accurate predictions for toxicity than other approaches. This
highly efficient and accurate service will allow for faster evaluation of compounds
for potential hazards, making drugs, cosmetics, flavors, fragrances and other
chemicals safer for consumers in the long run.”
Unlike other screening tests, the CAN MultiFlow™ assay analyses multiple
biomarkers (p53, hH2AX and Phospho-Histone H3) associated with DNA damage in
a single high-throughput assay. This model provides more accurate predictions of
genotoxicity to help avoid false positives or other misinformation that may exclude
an otherwise safe compound from a development pipeline. The CAN MultiFlow™
assay uses a minimal amount of material for testing and rapidly provides results.
The new CAN MultiFlow™ assay is based on the MultiFlow™ kit from Litron
Laboratories. At this time, Merck is the only provider of the service in the United
States. With the addition of this new service, Merck now offers the industry’s most
current and comprehensive range of solutions for genotoxicity assessment, from
discovery to lead optimization, and from regulatory assessment to lead rescue.
* mode of action properties are functional or anatomical changes that occur at the cellular
level as a result of exposure to a toxic substance.
All Merck news releases are distributed by email at the same time they become available on the Merck
Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or
discontinue this service.
